BRIEF-Ablynx initiates phase I study of anti-il-6R nanobody with Abbvie
April 23, 2014 at 01:44 AM EDT
* Ablynx initiates phase I bioavailability study with subcutaneous formulation of its anti-il-6R nanobody partnered with Abbvie
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.